Press release
Pharmacogenomics Market- Global Forecast to 2028 | Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Laboratory Corporation of America Holdings (US)
Pharmacogenomics Market in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR of 10.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. The increasing focus on the translational approach to optimize drug development processes, increasing collaborations and partnerships between key players and research institutes, and rising incidence of cancer are the major driving factors of the pharmacogenomics market. However, concern regarding drug response variability, and challenges in data integration and interpretation are the major restraining factors of the pharmacogenomics market.Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142682251&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral
The kits & reagents segment accounted for the largest share by product & service in the pharmacogenomics market in 2022.
By product & service, the pharmacogenomics market has been further categorized kits & reagents and service. Kits & reagents accounted for the largest share of the pharmacogenomics market in 2022. The pivotal role played by kits and reagents in the execution of pharmacogenomic tests, combined with the rising adoption of personalized medicine and advancements in genomic technologies, contributes significantly to the expansion of this segment within the pharmacogenomics market.
The sequencing segment is expected to grow at a higher rate during the forecast period.
Based on technology, the pharmacogenomics market has been segmented into sequencing, PCR, microarray, and other technologies. In 2022, the sequencing segment accounted for the largest share of the pharmacogenomics market is expected to grow at a higher growth rate during the forecast period of 2023-2028. Sequencing technologies play a crucial role in precisely and effectively handling genomic data, facilitating the identification of nucleotide alterations impacting drug metabolism and response. The progress in developing novel sequencing technologies and reagents further propels the evolution of pharmacogenomics research, facilitating the identification and functional understanding of genetic variants associated with drug metabolism and response.
The cancer segment accounted for the largest share of the disease area segment in the pharmacogenomics market in 2022.
Based on disease area, the pharmacogenomics market has been segmented into cancer, cardiovascular, neurological diseases, and other diseases. In 2022, the cancer segment accounted for the largest share of the pharmacogenomics market. The expansion of the pharmacogenomics market is fueled by a surge in research funding dedicated to the advancement of personalized drug products for cancer treatment. For instance, the National Cancer Institute (NCI) allocated an estimated USD 6,467 million from its research budget, covering diverse disease areas such as AIDS, brain & CNS, and cancer.
The North America region accounted for the largest share of the pharmacogenomics market in 2022.
The pharmacogenomics market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer has contributed to growth of the pharmacogenomics market.
Request Sample Pages: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142682251&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral
Pharmacogenomics Market Dynamics:
Drivers:
1. Growing incidence and prevalence of chronic and genetic diseases
2. Rising investments and funding to support genomic projects
3. Rising incidence of cancer
4. Increasing collaborations and partnerships between key players and research institutes
5. Increasing focus on translational approach to optimize drug development processes
Restraint:
1. Challenges in data integration and interpretation
2. Issues related to drug response variabilities
Opportunities:
1. Use of genomics in specialized/personalized medicine
2. AI in pharmacogenomics
3. Increasing cost-effectiveness of pharmacogenomics testing
Challenge:
1. Ethical and regulatory hurdles
2. Growing concerns related to patient privacy and data access
Key Market Players of Pharmacogenomics Industry:
Key players in the pharmacogenomics market Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), BD (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), IQVIA Inc. (US), Mesa Labs, Inc. (US), Medpace (US), MGI Tech Co., Ltd. (China), Takara Bio Inc. (Japan), PacBio (US), New England Biolabs (US), BGI (China), Novogene Co., Ltd. (China), SOPHiA GENETICS (Switzerland), Fios Genomics (UK), Personalis, Inc. (US), BioAI Health Inc. (US), NeoGenomics Laboratories (US), and Macrogen, Inc. (South Korea).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=142682251&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insights: https://www.marketsandmarkets.com/ResearchInsight/pharmacogenomics-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/pharmacogenomics.asp
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pharmacogenomics Market- Global Forecast to 2028 | Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Laboratory Corporation of America Holdings (US) here
News-ID: 3553134 • Views: …
More Releases from MarketsandMarkets

Laser Interferometer Market Set to Grow at the Fastest Rate- Time to Grow your R …
The global laser interferometer market is expected to be valued at 315 million in 2024 and is projected to reach USD 447 million by 2029, at a CAGR of 7.2% from 2024 to 2029. Emerging applications in industries push the market's growth due to the growing demand for precision in the manufacturing sector. However, challenges such as higher initial investments and maintenance costs cause problems. Despite these, opportunities arise for…

With 19.6% CAGR, Battery Testing, Inspection, and Certification Market Growth to …
The battery testing, inspection, and certification market is projected to reach USD 36.7 billion by 2029 from USD 14.9 billion in 2024 at a CAGR of 19.6% during the forecast period. Increasing adoption of EVs and energy storage systems, rising enforcement of stringent standards to ensure battery safety, thriving portable electronics industry, and rapid advances in battery technology are the major factors contributing to the market growth.
Download PDF Brochure @…

Real-Time Location Systems Revolutionize Healthcare: Insights from MarketsandMar …
The global RTLS market for healthcare is projected to grow from USD 2.3 billion in 2024 to USD 5.7 billion by 2029, at a compound annual growth rate of 19.6% from 2024 to 2029. As it attracts more and more players who enter this market with innovative RTLS features for customers, the market for RTLS technology is rapidly increasing. Top companies in this market focus on healthcare, retail, and manufacturing…

Offsite Data Center Power Infrastructure Market Size to Reach $35.4 billion by 2 …
According to a research report "Offsite Data Center Power Infrastructure Market by Component (Solutions and Services), Vertical (BFSI, Media & Entertainment, Government & Defence, Healthcare, Manufacturing, IT & Telecom, Retail) and Region - Global Forecast to 2030" published by MarketsandMarkets, the market size for global offsite data center power infrastructure market is projected to reach approximately USD 35.4 billion by the year 2030, as compared to the estimated value of…
More Releases for Pharmacogenomics
Pharmacogenomics - Top Companies Regional and Data Analysis
Pharmacogenomics is a branch of science, which studies the role of gene over the activity of a drugs and hence helps the refreshers in predicting the response of novel as well as previously available therapies.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00007564/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Pharmacogenomics Market are:
• F. Hoffmann-la Roche Ltd
• Abbott
• Oxford Nanopore Technologies
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• QIAGEN
• Agilent Technologies, Inc.
• Myriad Genetics, Inc.
• Admera Health
Contact Us:
If you have any queries about…
Pharmacogenomics Market worth $5.8 billion by 2028
North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer has contributed to growth of the pharmacogenomics market.
Pharmacogenomics Market [https://www.marketsandmarkets.com/Market-Reports/pharmacogenomics-market-142682251.html?utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral] in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR of 10.6% from 2023 to…
Genetic Medicine: Unveiling the Power of Pharmacogenomics
Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is subsegmented into real time PCR, standard PCR, and digital PCR. The PCR segment dominated the pharmacogenomics market in 2021 and is expected to register the highest CAGR during the forecast period.
Download Sample PDF Details at: https://www.theinsightpartners.com/sample/TIPRE00007564?utm_source=OpenPR&utm_medium=10776
The pharmacogenomics market is segmented on the basis of…
Complete PDF Guide On Pharmacogenomics [PDF]
According to our latest study on "Pharmacogenoics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Technology, Application, and End User," the market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is expected to grow at a CAGR of 10.3% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their…
Global Pharmacogenomics Market Size & Trends
According to a new market research report published by Global Market Estimates, the global pharmacogenomics market is projected to grow at a CAGR of 9.6% from 2023 to 2028.
The growth of the global pharmacogenomics market is driven by advancements in genomics and DNA sequencing technologies, the rising demand for personalized medicine, regulatory support from agencies like the FDA, cost-effectiveness through reduced adverse reactions, and a growing aging population with complex…
Global Pharmacogenomics Services Market Insights | 2022-2032
The Pharmacogenomics Services Market refers to the services provided by companies and laboratories that offer personalized medicine based on a patient's genetic makeup. Pharmacogenomics is the study of how an individual's genes affect their response to certain drugs, and the pharmacogenomics services market focuses on utilizing this knowledge to optimize drug therapy.
These services typically involve genetic testing to identify specific genetic variations that may impact a patient's response to certain…